Wockhardt Limited — Updates, 02-01-2025: Press Release

The Indian drug regulator has approved Wockhardt's new generation oral antibiotic Miqnaf® (nafithromycin) for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in adults. This ultra-short course, once-a-day treatment over three days is designed to address the challenges of antibiotic resistance faced in community pneumonia cases. Miqnaf® effectively targets a wide range of pathogens, including those resistant to existing treatments like azithromycin and amoxicillin/clavulanate, thereby potentially reducing hospitalizations associated with intravenous therapies.

Following extensive clinical studies across several regions, Wockhardt plans to launch Miqnaf® in the Indian market in the coming months, marking a significant entry in the antibiotic landscape after three decades. Given the global burden of CABP, particularly in India, this approval positions Wockhardt to capitalize on a critical healthcare need while enhancing patient compliance with its simplified treatment regimen. Investors should watch this development closely, as the market introduction could offer substantial growth opportunities for Wockhardt amid rising antibiotic resistance concerns.